Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Protein Tyrosine Kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (9) Btk (3) DYRK (1) FAK (3) FLT3 (9) Syk (1) Tyrosine Hydroxylase (1) Amyloid-β (1) Apoptosis (11) Autophagy (7) Bacterial (3) Bcr-Abl (10) c-Fms (1) c-Kit (9) c-Met/HGFR (19) c-Myc (1) Calcineurin (1) Calcium Channel (3) Calmodulin (1) CaMK (3) Caspase (1) CD3 (1) CDK (6) COX (1) Cyclic GMP-AMP Synthase (3) Discoidin Domain Receptor (1) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (1) EGFR (22) Endogenous Metabolite (1) Ephrin Receptor (1) ERK (5) Ferlin Family (1) FGFR (18) GLUT (2) HIV (1) IGF-1R (1) Insulin Receptor (2) Isotope-Labeled Compounds (2) Itk (1) JAK (11) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) MAP3K (1) MAP4K (1) MHC (1) MMP (1) Molecular Glues (1) mRNA (8) Myosin (1) NO Synthase (1) PDGFR (16) Phosphatase (4) Phosphodiesterase (PDE) (2) Phospholipase (2) PI3K (1) PIN1 (1) PKA (5) PKC (7) Polo-like Kinase (PLK) (1) PROTACs (3) Proteasome (2) RAD51 (3) Ras (1) Reference Standards (7) RET (22) Reverse Transcriptase (1) SARS-CoV (4) Ser/Thr Kinase (3) Ser/Thr Protease (1) SHP2 (1) Src (19) STAT (2) TAM Receptor (3) Tau Protein (1) TGF-β Receptor (1) Topoisomerase (1) Trk Receptor (4) Tyrosinase (3) VEGFR (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (144) Cardiovascular Disease (10) Endocrinology (1) Infection (12) Inflammation/Immunology (21) Metabolic Disease (10) Neurological Disease (7)
Oligonucleotides:	Aptamers (2) mRNA (8) Interleukin & Receptors (1)

188

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Btk Syk Pyk2 TNK1 Tyrosine Hydroxylase DYRK BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14435

Pyridone 6 10+ Cited Publications	JAK	Cancer
Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-N6732

K-252a Maximum Cited Publications 27 Publications Verification SF2370; Antibiotic K 252a; Antibiotic SF 2370	Autophagy PKA PKC Trk Receptor CaMK	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits **protein kinase, with IC₅₀** values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-137677B

GTPγS tetralithium Guanosine 5'-[γ-thio]triphosphate tetralithium	GLUT	Metabolic Disease
GTPγS (Guanosine 5'-[γ-thio]triphosphate) tetralithium is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS tetralithium to couple with G- protein α, to study its effect on kinase activity. GTPγS tetralithium acts as a component of lysis buffer .

HY-160144S

Lomedeucitinib BMS-986322	Isotope-Labeled Compounds JAK	Inflammation/Immunology
Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor .

HY-P2503

*EGFR Protein* Tyrosine Kinase Substrate**	EGFR	Cancer
EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.

HY-N2506

Ginsenoside Ra1	Others	Cardiovascular Disease
Ginsenoside Ra1 is a component from ginseng, inhibits protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation .

HY-18963

Lavendustin A 1 Publications Verification RG-14355	EGFR	Cancer
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC₅₀s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-101246

RPI-1	RET	Cancer
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .

HY-N7160

2-Hydroxy-3-methylanthraquinone	Src Apoptosis	Cancer
2-Hydroxy-3-methylanthraquinone (compound 1) is a natural compound isolated from a water extract of Hedyotis diffusa WILLD. 2-Hydroxy-3-methylanthraquinone shows inhibitory activity against **protein tyrosine kinases v-src and pp60src, and induces growth arrest and apoptosis** in the HepG2 cancer cells .

HY-P5426

*Abl protein* tyrosine kinase substrate**	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-103097

ST271	Phospholipase	Others
ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC₅₀s of 6.7 and 9 μM, respectively.

HY-P0200

RR-SRC	Src	Inflammation/Immunology
RR-SRC is a substrate for src-tyrosine-specific protein kinase .

HY-133083

BAY-474 1 Publications Verification	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe .

HY-P1590

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-E70873

Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase	JAK	Cancer
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant Tyk2(JH1/JH2) protein that can be used to study Tyk2(JH1/JH2)-related functions .

HY-180888

Lck-IN-5	Src CD3	Inflammation/Immunology
Lck-IN-5 (example C10) is a potent and selective lymphocyte-specific protein tyrosine kinase (LCK) inhibitor. Lck-IN-5 selectively disrupts the interaction between the SH3 domain of LCK and the RK motif of CD3ε, thereby impairing LCK recruitment to the TCR. Lck-IN-5 modulates the activity of CD3ε-containing CAR and TRuC T cells, attenuating cytokine production and promoting a central-memory-like phenotype associated with enhanced persistence. Lck-IN-5 can be used for autoimmune diseases and graft-versus-host disease research .

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-P1803

Protein Kinase C Peptide Substrate PKCε; PRKCE ; Peptide Epsilon	PKC	Neurological Disease Inflammation/Immunology Endocrinology
Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins in response to extracellular signals that activate G-protein-coupled receptors, tyrosine kinase receptors, or tyrosine kinase-coupled receptors. Protein Kinase C Peptide Substrate then regulates various physiological functions including the activation of nervous, endocrine, exocrine, inflammatory, and immune systems .

HY-18316

RO495	JAK	Inflammation/Immunology
RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase) .

HY-E70869

TRKA(NTRK1) Recombinant Human Active Protein Kinase	Trk Receptor	Neurological Disease
TRKA (also named NTRK1) is a potential new member of the tyrosine kinase gene family. TRKA is a receptor tyrosine kinase that is phosphorylated in response to NGF. A single transmembrane domain divides TRKA into an extracellular domain, important for NGF binding, and an intracellular tyrosine kinase domain, important for signal transduction. TRKA(NTRK1) Recombinant Human Active Protein Kinase is a recombinant TRKA(NTRK1) protein that can be used to study TRKA(NTRK1)-related functions .

HY-E70833

ITK Recombinant Human Active Protein Kinase	Itk	Cancer
ITK is the Tec family tyrosine kinase that has been implicated in T cell receptor (TCR) signaling. ITK Recombinant Human Active Protein Kinase is a recombinant ITK protein that can be used to study ITK-related functions .

HY-152830A

Adrixetinib TFA Q702 TFA	c-Fms TAM Receptor MHC	Cancer
Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with K_d values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .

HY-W174279

Tyrphostin 8	EGFR Ras Phosphatase	Metabolic Disease
Tyrphostin 8 is a **tyrosine kinase, with an IC₅₀** of 560 μM for EGFR kinase. Tyrphostin 8 is also a GTPase inhibitor. Tyrphostin 8 can inhibit the protein serine/threonine phosphatase calcineurin (IC₅₀=21 μM) .

HY-160689

GW694590A UNC10112731	c-Myc c-Kit Discoidin Domain Receptor PDGFR	Others
GW694590A (UNC10112731) is a MYC protein stabilizer that increases endogenous MYC protein levels. GW694590A also targets receptor tyrosine kinases, inhibiting DDR2, KIT and PDGFRα by 81% at 1 μM. , 68% and 67%. GW694590A is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential effects on the Fluc reporter gene .

HY-E70763

PDGFRalpha T674I Recombinant Human Active Protein Kinase	PDGFR	Cancer
PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha T674I is a mutant of PDGFRalpha. PDGFRalpha T674I Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha T674I protein that can be used to study PDGFRalpha T674I-related functions .

HY-E70823

FGFR2 N549K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

HY-E70870

TRKB(NTRK2) Recombinant Human Active Protein Kinase	Trk Receptor	Neurological Disease
TRKB(NTRK2) is a member of tyrosine kinase gene family. TRKB is the primary receptor for brain-derived nerve growth factor (BDNF) and neurotrophin 4/5 (NT4/5). TRKB(NTRK2) Recombinant Human Active Protein Kinase is a recombinant TRKB(NTRK2) protein that can be used to study TRKB(NTRK2)-related functions .

HY-163278

Lck-IN-2	Src Apoptosis	Cancer
Lck-IN-2 (compound 12a) is an inhibitor of Lymphocyte-specific protein tyrosine kinase (Lck) with IC₅₀ of 10.6 nM. Lck-IN-2 reveals efficacy in colon cancer cells with GI₅₀s of 0.24-1.26 μM. Lck-IN-2 exhibits an apoptotic effect in Colo201 cells .

HY-121828

TX-1123	Src CaMK PKA EGFR PKC COX	Cancer
TX-1123 is a potent protein tyrosine kinase (PTK) inhibitor for Src, eEF2-K, and PKA, and EGFR-K/PKC. TX-1123 is a cyclo-oxygenase (COX) inhibitor with IC₅₀ values of 1.16 μM and 15.7 μM for COX2 and COX1, respectively. TX-1123 has low mitochondrial toxicity. TX-1123 can be used in research of cancer .

HY-147612

Tyrosine kinase-IN-4	c-Met/HGFR	Cancer
Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein **tyrosine kinase** inhibitor .

HY-N14635

Paeciloquinone A	EGFR	Infection
Paeciloquinone A can inhibit EGFR protein tyrosine kinase. Paeciloquinone A inhibits the V-abl protein tyrosine kinase with an IC₅₀ of 0.59 μM .

HY-N14637

Paeciloquinone C	EGFR	Infection
Paeciloquinone C can inhibit the EGFR protein tyrosine kinase. Paeciloquinone C inhibits the V-abl protein tyrosine *K_i*nase with an IC₅₀ of 0.56 μM .

HY-N14638

Paeciloquinone D	EGFR	Infection
Paeciloquinone D can inhibit the EGFR protein tyrosine kinase .

HY-N14639

Paeciloquinone E	EGFR	Infection
Paeciloquinone E can inhibit the EGFR protein tyrosine kinase .

HY-N14640

Paeciloquinone F	EGFR	Infection
Paeciloquinone F can inhibit the EGFR protein tyrosine kinase .

HY-N14636

Paeciloquinone B	EGFR	Infection
Paeciloquinone B can inhibit the EGFR protein tyrosine kinase .

HY-171294

Protein kinase inhibitor 16	Ser/Thr Kinase	Inflammation/Immunology Cancer
Protein kinase inhibitor 16 exhibits inhibitory activity against a variety of Ser/Thr kinase or receptor or non-receptor tyrosine kinase .

HY-N14271

Hibarimicin B Angelmicin B	Src Bacterial	Infection Cancer
Hibarimicin B (Angelmicin B) is a tyrosine kinase inhibitor. It selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. It also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-171291

Protein kinase inhibitor 14	Ser/Thr Kinase	Inflammation/Immunology Cancer
Protein kinase inhibitor 14 (Compound 13) exhibits inhibitory effects against a variety of serine/threonine kinase and receptor/non-receptor tyrosine kinase .

HY-N14273

Hibarimicin C	Src Bacterial	Infection Cancer
Hibarimicin C is a tyrosine kinase inhibitor. Hibarimicin C selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin C also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-N14689

Hibarimicin D	Src	Infection Cancer
Hibarimicin D is a tyrosine kinase inhibitor. Hibarimicin D selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin D also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-111158

BMS-748730	c-Met/HGFR	Cancer
BMS-748730 is an oral **tyrosine kinase inhibitor. BMS-748730 inhibits tyrosine kinase activity by competing with the ATP binding site of the tyrosine kinase*, which prevents the kinase* from phosphorylating the substrate protein, thereby inhibiting signaling pathways associated with cell proliferation and tumor growth. BMS-748730 can be used in the study of certain types of cancer, including chronic myeloid leukemia (CML) .

HY-E70725

FRK Recombinant Human Active Protein Kinase	Src	Cancer
FRK Recombinant Human Active Protein Kinase, a non-receptor tyrosine kinase Fyn-related kinase, is a member of the BRK family kinases (BFKs). FRK may be involved in tumor progression .

HY-N14267

Hibarimicin A	Src Bacterial	Infection Cancer
Hibarimicin A is a tyrosine kinase inhibitor found in Microbispora rosea subsp. hibaria. Hibarimicin A selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin A also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-171293

Protein kinase inhibitor 15	Ser/Thr Kinase	Inflammation/Immunology Cancer
Protein kinase inhibitor 15 (Compound A.35.3) exhibits inhibitory activity against a variety of Ser/Thr kinase or receptor or non-receptor tyrosine kinase .

HY-401475

Protein kinase inhibitor 9	PKC	Cardiovascular Disease Inflammation/Immunology Cancer
Protein kinase inhibitor 9 (Compound example 175) is an inhibitor of serine/threonine and tyrosine kinase activity. Protein kinase inhibitor 9 can be used for the research of cancer, hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders .

HY-124152

3,4-Dephostatin Methyl-3,4-dephostatin	MAP3K MAP4K Phosphatase	Neurological Disease
3,4-Dephostatin (Methyl-3,4-dephostatin) is an inhibitor of protein-tyrosine phosphatase (PTPase). 3,4-Dephostatin accelerates nerve growth factor (NGF)-induced neurite formation in PC12h cells. 3,4-Dephostatin sustains the NGF-induced tyrosine phosphorylation of proteins, most prominently that of mitogen-activated protein (MAP) kinase. 3,4-Dephostatin also prolongs epidermal growth factor (EGF)-induced tyrosine phosphorylation and activation of MAP kinase .

HY-125350

Entacapone acid Tyrphostin AG1290	c-Met/HGFR	Metabolic Disease
Entacapone acid (Tyrphostin AG1290) is a **tyrosine kinase** inhibitor. Entacapone acid reduces hepatic protein synthesis rate (HPS) in vivo .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L081

Phosphatase Inhibitor Library

175 compounds

Protein phosphorylation is a key post-translational modification underlying the regulation of many cellular processes. Phosphatases and kinases contribute to the regulation of protein phosphorylation homeostasis in the cell. This reversible regulation of protein phosphorylation is critical for the proper control of a wide range of cellular activities, including cell cycle, proliferation and differentiation, metabolism, cell-cell interactions, etc.

Protein phosphatases have evolved in separate families that are structurally and mechanistically distinct. Based on substrate specificity and functional diversity, protein phosphatases are classified into two superfamilies: Protein serine/threonine phosphatases and Protein tyrosine phosphatases. Ser/Thr phosphatases are metalloenzymes belonging to two major gene families termed PPP (phosphoprotein phosphatase) and PPM (metal-dependent protein phosphatases), whereas protein tyrosine phosphatases (PTPs) belong to distinct classes of enzymes that utilize a phospho-cysteine enzyme intermediate as a part of their catalytic action.

MCE supplies a unique collection of 175 phosphatase inhibitors that mainly targeting protein tyrosine phosphatases (PTPs) and serine/threonine-specific protein phosphatases. MCE Phosphatase Inhibitor Library is a useful tool for phosphatase drug discovery and related research.

HY-L075

Anti-Lung Cancer Compound Library

2,886 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L015

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P2503

*EGFR Protein* Tyrosine Kinase Substrate**	EGFR	Cancer
EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-P5426

*Abl protein* tyrosine kinase substrate**	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-P0200

RR-SRC	Src	Inflammation/Immunology
RR-SRC is a substrate for src-tyrosine-specific protein kinase .

HY-P1590

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-P3743

p60c-src Substrate	Src Peptides	Others
p60c-src Substrate is an efficient and specific substrate for p60c-src protein tyrosine kinase (PTK). p60c-src Substrate can be used to synthesize chimeric branched peptides .

HY-P1803

Protein Kinase C Peptide Substrate PKCε; PRKCE ; Peptide Epsilon	PKC	Neurological Disease Inflammation/Immunology Endocrinology
Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins in response to extracellular signals that activate G-protein-coupled receptors, tyrosine kinase receptors, or tyrosine kinase-coupled receptors. Protein Kinase C Peptide Substrate then regulates various physiological functions including the activation of nervous, endocrine, exocrine, inflammatory, and immune systems .

HY-P3787

Ac-Asp-Tyr(PO3H2)-Val-Pro-Met-Leu-NH2	Peptides	Metabolic Disease
Ac-Asp-Tyr(PO3H2)-Val-Pro-Met-Leu-NH2 is the SH2 domain ligand. SH2 domains participate in protein tyrosine kinase (PTK)-mediated cellular signal .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992116

Ladarutatug	TAM Receptor	Cancer
Ladarutatug is a humanized monoclonal antibody targeting Tyrosine-protein kinase receptor UFO. The Ladarutatug antibody isotype is human IgG4κ; the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6732

K-252a Maximum Cited Publications 27 Publications Verification SF2370; Antibiotic K 252a; Antibiotic SF 2370	Alkaloids Structural Classification Microorganisms Classification of Application Fields Inflammation/Immunology Disease Research Fields Indole Alkaloids Source Classification	Autophagy PKA PKC Trk Receptor CaMK
K-252a, a staurosporine analog, inhibits **protein kinase, with IC₅₀** values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-16558

Butein 5+ Cited Publications 2’,3,4,4’-tetrahydroxy Chalcone	Chalcones Flavonoids other families Classification of Application Fields Anti-aging Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N2506

Ginsenoside Ra1	Cardiovascular Disease Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Others
Ginsenoside Ra1 is a component from ginseng, inhibits protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation .

HY-18963

Lavendustin A 1 Publications Verification RG-14355	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Disease Research Fields Source Classification Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-N1400

(20R)-Ginsenoside Rh1	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification Cancer	PKC
(20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .

HY-N4201

β-Hydroxyisovalerylshikonin	Quinones Classification of Application Fields Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Disease Research Fields Boraginaceae Cancer Source Classification	EGFR Src
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC₅₀s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells .

HY-N7160

2-Hydroxy-3-methylanthraquinone	Quinones Anthraquinones Rubiaceae Plants Source Classification Hedyotis diffusa Willd.	Src Apoptosis
2-Hydroxy-3-methylanthraquinone (compound 1) is a natural compound isolated from a water extract of Hedyotis diffusa WILLD. 2-Hydroxy-3-methylanthraquinone shows inhibitory activity against **protein tyrosine kinases v-src and pp60src, and induces growth arrest and apoptosis** in the HepG2 cancer cells .

HY-16558R

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Structural Classification Chalcones Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N14635

Paeciloquinone A	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone A can inhibit EGFR protein tyrosine kinase. Paeciloquinone A inhibits the V-abl protein tyrosine kinase with an IC₅₀ of 0.59 μM .

HY-N14637

Paeciloquinone C	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone C can inhibit the EGFR protein tyrosine kinase. Paeciloquinone C inhibits the V-abl protein tyrosine *K_i*nase with an IC₅₀ of 0.56 μM .

HY-N14638

Paeciloquinone D	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone D can inhibit the EGFR protein tyrosine kinase .

HY-N14639

Paeciloquinone E	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone E can inhibit the EGFR protein tyrosine kinase .

HY-N14640

Paeciloquinone F	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone F can inhibit the EGFR protein tyrosine kinase .

HY-N14636

Paeciloquinone B	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone B can inhibit the EGFR protein tyrosine kinase .

HY-N14271

Hibarimicin B Angelmicin B	Quinones Structural Classification Microorganisms Naphthalene Quinones Source Classification	Src Bacterial
Hibarimicin B (Angelmicin B) is a tyrosine kinase inhibitor. It selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. It also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-N14273

Hibarimicin C	Quinones Structural Classification Microorganisms Naphthalene Quinones Source Classification	Src Bacterial
Hibarimicin C is a tyrosine kinase inhibitor. Hibarimicin C selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin C also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-N14689

Hibarimicin D	Natural Products Microorganisms Source Classification	Src
Hibarimicin D is a tyrosine kinase inhibitor. Hibarimicin D selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin D also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-N14267

Hibarimicin A	Quinones Structural Classification Microorganisms Naphthalene Quinones Source Classification	Src Bacterial
Hibarimicin A is a tyrosine kinase inhibitor found in Microbispora rosea subsp. hibaria. Hibarimicin A selectively inhibits the activity of src tyrosine kinase without affecting protein kinase A and C. Hibarimicin A also has moderate anti-Gram-positive bacteria activity with a MIC of 0.8-12.56 μg/mL .

HY-18963R

Lavendustin A (Standard) RG-14355 (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Phenols Polyphenols Source Classification	Reference Standards EGFR
Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].

Cat. No.	Product Name	Chemical Structure

HY-160144S

Lomedeucitinib
Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor .

HY-160144S2

(rac)-Lomedeucitinib
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus .

HY-15463S3

Imatinib-13C,d3

Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-160144S1

(S)-Lomedeucitinib
(S)-Lomedeucitinib ((S)-BMS-986322) is a S-enantiomer of Lomedeucitinib (HY-160144S). Lomedeucitinib is a tyrosine protein kinase (TYK2) inhibitor .

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

Cat. No.	Product Name		Classification

HY-160065

sgc8c aptamer sodium		Aptamers
sgc8c aptamer sodium is an aptamer that specifically targets the human protein tyrosine kinase PTK-7, which is mainly expressed on cervical cancer HeLa cells. sgc8c aptamer sodium can precisely bring the nanotags connected to it to the surface of cells expressing PTK-7, thus achieving specific recognition and labeling of target cells .

HY-174548

Human PDGFRB mRNA		mRNA
Human PDGFRB mRNA encodes the human platelet derived growth factor receptor beta (PDGFRB) protein, a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. PDGFRB is essential for normal development of the cardiovascular system and aids in rearrangement of the actin cytoskeleton.

HY-174549

Human PDGFRA mRNA		mRNA
Human PDGFRA mRNA encodes the human platelet derived growth factor receptor alpha (PDGFRA) protein, a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. PDGFRA may play a role in organ development, wound healing, and tumor progression.

HY-174684

Human FLT1 mRNA		mRNA
Human FLT1 mRNA encodes the human fms related receptor tyrosine kinase 1 (FLT1) protein, a member of the vascular endothelial growth factor receptor (VEGFR) family. FLT1 binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis.

HY-174687

Human FGFR4 mRNA		mRNA
Human FGFR4 mRNA encodes the human fibroblast growth factor receptor 4 (FGFR4) protein, a tyrosine kinase and cell surface receptor for fibroblast growth factors. FGFR4 is involved in the regulation of several pathways, including cell proliferation, cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis, vitamin D metabolism, glucose uptake, and phosphate homeostasis.

HY-174581

Human MET mRNA		mRNA
Human MET mRNA encodes the human MET proto-oncogene, receptor tyrosine kinase (MET) protein, a member of the receptor tyrosine kinase family. MET regulates many physiological processes including proliferation, scattering, morphogenesis and survival.

HY-174683

Human FLT4 mRNA		mRNA
Human FLT4 mRNA encodes the human Fms related receptor tyrosine kinase 4 (FLT4) protein, a tyrosine kinase receptor for vascular endothelial growth factors C and D. FLT4 is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium.

HY-174721

Human EGFR mRNA		mRNA
Human EGFR mRNA encodes the human epidermal growth factor receptor (EGFR) protein, a member of the protein kinase superfamily. IGF1R plays a critical role in transformation events. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation.

HY-177870

Sgc8c Aptamer		Aptamers
Sgc8c Aptamer is a single-stranded DNA aptamer targeting protein tyrosine kinase 7 (PTK7) with K_d of 1.03-11.73 nM for human, mice, rat and monkey. Sgc8c Aptamer can be used to synthesize aptamer-drug conjugates and can be used for cancer research .

HY-174638

Human IL13RA1 mRNA		mRNA Interleukin & Receptors
Human IL13RA1 mRNA encodes the human interleukin 13 receptor subunit alpha 1 (IL13RA1) protein, a subunit of the interleukin 13 receptor. IL13RA1 serves as a primary IL13-binding subunit of the IL13 receptor, and may also be a component of IL4 receptors. It has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks